register

News & Trends - Pharmaceuticals

Noxopharm secures $23 million to fund clinical studies in several cancers

Health Industry Hub | December 6, 2020 |

Pharma News: Australian clinical stage drug development company Noxopharm has successfully completed a A$23 million share placement to professional, institutional and sophisticated investors.

Noxopharm CEO, Dr Graham Kelly said: ”The support received from new, high-quality investors as well as some existing shareholders demonstrates a shared vision in the potential of our technology. That vision is to see Veyonda become the drug of choice to restore cancer-eradicating immune function to tumours, the so-called cold-to-hot effect. This absence of immune function in most human tumours is now recognised as the primary factor holding back current cancer therapies from working to full effect in most patients.

“The significance of what we are doing is that Veyonda, with its unique cold-to-hot effect, is the first opportunity medicine has had of seeing whether this problem can be rectified across a range of major cancer types. If Veyonda proves to be the answer we believe it to be, then the face of cancer therapy is set to change in a dramatic way.”

The funds raised in this placement are intended to provide sufficient runway to show whether that vision can be realised.

The Company is testing the benefit of the cold-to-hot action across three programs:

  1. The first is with checkpoint inhibitors. The IONIC Program is testing Veyonda in combination with the Bristol Myers-Squibb immuno-oncology drug, Opdivo.
  2. The second is with external radiotherapy. The DARRT Program is testing Veyonda in combination with external beam radiotherapy
  3. The third is with intravenous radiotherapy. The LuPIN Program is testing Veyonda in combination with the Novartis’ radiopharmaceutical drug, 177Lu-PSMA-617.

“Planning for both IONIC and DARRT studies has been in the works for many months, but this fresh injection of funds will ensure that both studies can start recruiting patients as soon as possible in the new year. When combined with next year’s anticipated Federal Government R&D Rebate, we expect to be funded through into 2022,” Kelly added.

Use of Funds

Placement proceeds will be applied to the following activities:

  • Commencement of the Phase I/II IONIC-1 study to be conducted in 3 Australian hospitals in 30 patients with a variety of late-stage cancers
  • Commencement of the Phase II DARRT-2 multinational study to be conducted in up to 200 patients with late-stage prostate, breast or lung cancers
  • Completion of the Phase II LuPIN study in 56 men with late-stage prostate cancer
  • Completion of the NOXCOVID-1 study in European hospitals in 40 patients experiencing moderate lung dysfunction associated with COVID-19 disease
  • Two exciting drug discovery programs intended to supply additional first-in-class pipeline drug candidates in the fields of (i) brain cancer, and (ii) pancreatic and gallbladder cancers.

News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.